Manufacturer with High Purity and Stable Quality
Chemical Name: Memantine Hydrochloride
Synonyms: Memantine HCl; 3,5-Dimethyl-1-adamantanamine Hydrochloride
CAS: 41100-52-1
Memantine Hydrochloride in the treatment of Alzheimer's disease
API USP Standard, High Quality, Commercial Production
| Chemical Name |
Memantine Hydrochloride |
| Synonyms |
Memantine HCl; 3,5-Dimethyl-1-adamantanamine Hydrochloride |
| CAS Number |
41100-52-1 |
| CAT Number |
RF-API43 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C12H22ClN |
| Molecular Weight |
215.76 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White or Off-White Crystal Powder |
| Identification |
IR |
| Loss on Drying |
≤0.50% |
| Heavy Metals (Pb) |
≤10ppm |
| Residual Solvent Ethanol |
≤0.05% |
| Residual Solvent Ethylacetate |
≤0.05% |
| Contamination Microbiologica |
Max 102 aerobes and fungi per 1g
No Escherichia coli |
| Size of Distributed Particles |
Pass 100um |
| pH |
4.5~6.5 |
| Assay |
99.0%~101.0% |
| Test Standard |
USP Standard |
| Usage |
Active Pharmaceutical Ingredient (API) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Memantine Hydrochloride (CAS: 41100-52-1) with high quality.
Memantine Hydrochloride (CAS: 41100-52-1) is a well- known neuroprotective drug used for the treatment of Alzheimer’s disease. It is believed to be the first neuroprotective drug that has achieve clinical approval by US FDA as well as European. The development of Alzheimer’s disease involves the misfolded mutant proteins such as β-amyloid peptide (Aβ, particularly Aβ1−42). These misfolded mutant protein can increase the NMDA response and further cause severe excitotoxicity. Memantine suppresses this process through acting as the antagonist of the N-methyl-d- aspartate-sensitive glutamate receptor (NMDARs). Memantine Hydrochloride (CAS: 41100-52-1) is also under investigation as a potential treatment for other kind of neurodegenerative disorders such as HIV-associated dementia, neuropathic pain, glaucoma, depression, Huntington’s disease, ALS and movement disorders, among other.
Memantine Hydrochloride, a NMDA receptor antagonist, was co-developed by Forest Laboratories with Merz Pharmaceuticals and marketed under the trade name Namenda for the treatment of Alzheimer’s disease in the US after its approval in October, 2003. This drug has been available in many European and Asian markets before getting approval in the US.